| abstract |
Compounds of formula (I) are provided that function as potent antagonists of the CCR9 receptor and present compounds confirmed in animal testing of inflammation, which is one of the characteristic disease states for CCR9. Wherein the variable L, X, Y and Z are as defined in the claims. These compounds are generally aryl sulfonamide derivatives and include pharmaceutical compositions; Methods of treating CCR9-mediated diseases; Useful as a control in assays for the identification of CCR9 antagonists. |